Clinical trials
Neuroendocrine Tumor Grade 2 clinical trials
Below are recruiting neuroendocrine tumor grade 2 clinical trials, each written for real people, not researchers. We’re tracking 80 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06406465RecruitingPhase 2
Belinostat trial for neuroendocrine cancer based on genetics
This trial tests a drug called belinostat, possibly combined with other drugs, based on your genetic makeup. It aims to find the right dose for people with a rare and aggressive neuroendocrine cancer that started outside the lungs.
Bethesda, MarylandAges 18–120 - NCT06943755RecruitingPhase 2/Phase 3
Zanzalintinib vs Everolimus for Neuroendocrine Tumors
This trial compares a new targeted therapy (zanzalintinib) with an existing drug (everolimus) for people with advanced neuroendocrine tumors (NETs). It aims to see which treatment works better and may offer a new option for patients whose cancer has grown despite previous treatments.
Birmingham, AlabamaAges 18 years+ - NCT05243082Recruiting
Ultrasound-guided heating treatment for pancreatic neuroendocrine tumors
This trial tests a procedure that uses an endoscope and ultrasound to heat (radiofrequency ablate) pancreatic neuroendocrine tumors. It may help shrink tumors while aiming to be a less invasive option.
OsloAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Birmingham, AlabamaAges 18 years+ - NCT07150546RecruitingPhase 1
Radiation and Peptide Therapy for Large Gut Neuroendocrine Tumors
This trial combines external radiation with a targeted radioactive drug (PRRT) to treat large, slow-growing neuroendocrine tumors in the gut that have spread and are not removable by surgery. It aims to see if this combination works better than either treatment alone.
Atlanta, GeorgiaAges 18 years+ - NCT06016855RecruitingPhase 4
Surgery before radiation therapy for neuroendocrine tumors
This trial tests if removing as much tumor as possible through surgery before a targeted radiation therapy (PRRT) can help people with well-differentiated neuroendocrine tumors that have spread to the liver. The goal is to see if this approach works better than radiation therapy alone.
Nashville, TennesseeAges 18 years+ - NCT05773274RecruitingPhase 2
Retreating with 177Lu-DOTATATE radiation versus usual treatment
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
Birmingham, AlabamaAges 18 years+ - NCT04086485RecruitingPhase 1/Phase 2
Lu-177 dotatate plus olaparib for inoperable neuroendocrine tumors
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
Bethesda, MarylandAges 18–100 - NCT04090034Recruiting
PRRT for advanced neuroendocrine tumors
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
Dallas, TexasAges 18 years+ - NCT04339036RecruitingPhase 2
CapTem plus Y-90 for liver-spread neuroendocrine tumors
This Phase 2 study tests whether combining capecitabine/temozolomide (“CapTem”) with Y-90 treatment can shrink neuroendocrine tumor (NET) spread in the liver. It may help people whose tumor is mostly in the liver and cannot be fully removed with surgery.
La Jolla, CaliforniaAges 18 years+ - NCT04464122Recruiting
Testing blood markers to diagnose and gauge early response in NEN
This trial studies whether specific blood “biomarkers” can help confirm a type of cancer called NEN (neuroendocrine neoplasm) and show whether treatment is working early. It may help doctors start or adjust treatment sooner, especially for cancers that are advanced or have spread.
Rome, ItalyAges 18–80 - NCT05048901RecruitingPhase 1/Phase 2
Cabozantinib plus lanreotide for advanced neuroendocrine tumors
This trial studies whether cabozantinib plus lanreotide can slow or shrink gastroenteropancreatic neuroendocrine tumors that have gotten worse despite previous treatments. If you qualify, you’ll be closely monitored for tumor response and side effects.
ChanghuaAges 20 years+ - NCT05387603RecruitingPhase 3
Targeted radiation for certain advanced neuroendocrine tumors
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
GothenburgAges 18 years+ - NCT05477576RecruitingPhase 3
Lu-177–treated NET patients: new drug versus standard care
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
Phoenix, ArizonaAges 18 years+ - NCT05636618RecruitingPhase 1/Phase 2
Targeted radiation for certain receptor-positive tumors
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
Jacksonville, FloridaAges 18–90 - NCT05687123RecruitingPhase 1
Adding sunitinib to Lutathera for pancreatic neuroendocrine tumors
This early-phase study tests whether adding sunitinib (a targeted pill) to Lutathera (a radioactive treatment) works better for people with advanced pancreatic neuroendocrine tumors. It also checks safety, since this combination has not been widely studied yet.
Duarte, CaliforniaAges 18 years+ - NCT05746208RecruitingPhase 2
Lenvatinib plus pembrolizumab for advanced grade 3 NET tumors
This trial studies lenvatinib plus pembrolizumab to treat well-differentiated grade 3 neuroendocrine tumors (NETs) that cannot be fully removed by surgery or are locally advanced. It aims to shrink the tumor or slow its growth after the disease shows progression.
San Francisco, CaliforniaAges 18 years+ - NCT06395402RecruitingPhase 2
Personalized dosing of lutathera for neuroendocrine tumors
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
Iowa City, IowaAges 18 years+ - NCT06472388RecruitingPhase 2
Testing two doses of everolimus for neuroendocrine tumors
This trial compares two daily doses (5 mg vs 10 mg) of everolimus, a targeted therapy, to see which works better and is safer for people with advanced neuroendocrine tumors (NETs). You may qualify if your cancer has grown despite previous treatment and you are in relatively good health.
São Paulo, São PauloAges 16 years+ - NCT06540937RecruitingPhase 2
Leflunomide for MEN-1 related neuroendocrine tumors
This trial tests if leflunomide, a medication usually used for arthritis, can shrink or slow the growth of neuroendocrine tumors in people with MEN-1 gene mutations. It is for patients whose tumors have worsened after standard treatment.
BeijingAges 18–75 - NCT06855095RecruitingPhase 2/Phase 3
PRRT with long-acting hormone therapy for neuroendocrine tumors
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
AmsterdamAges 18 years+ - NCT06889493RecruitingPhase 1
SVV-001 plus immunotherapy for neuroendocrine cancers
This trial tests a new virus-based treatment (SVV-001) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced neuroendocrine cancers that have gotten worse after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Miami, FloridaAges 18 years+ - NCT07185672RecruitingPhase 3
PRRT with or without chemotherapy for GEP NET
This trial tests whether adding chemotherapy to a standard treatment (PRRT) works better than PRRT alone for people with certain types of digestive tract or pancreatic neuroendocrine tumors. It is for those whose tumors have higher activity on scans or are growing.
Mumbai, MaharashtraAges 18 years+ - NCT07121478Enrolling by invitationPhase 2
Testing a new treatment for pancreatic neuroendocrine tumors
This trial is for people with high-grade pancreatic neuroendocrine tumors (a type of pancreas cancer) whose previous treatments stopped working. It tests whether a new approach can help when standard options have failed.
Goyang-si, Gyeonggi-doAges 19 years+
Hear when a new Neuroendocrine Tumor Grade 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuroendocrine tumor grade 2?
- Yes. Clin2 currently lists 80 recruiting neuroendocrine tumor grade 2 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuroendocrine tumor grade 2 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuroendocrine tumor grade 2 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.